Dalbeth N, Horne A, Mihov B, et al. - This study was undertaken to determine if moderate hyperuricaemia induced by inosine supplements influences bone turnover markers in postmenopausal women over a six‐month period. One hundred and twenty postmenopausal women were selected into a six‐month randomised, double‐blind, placebo‐controlled trial. Osteoporosis, prior fragility fracture, bisphosphonate therapy, gout, kidney stones, and urine pH ≤ 5.0 were the main exclusion criteria. Candidates were randomised 1:1 to placebo or inosine. Over the study period, administration of inosine led to a significant increase in serum urate. This clinical trial demonstrates that although inosine supplementation leads to a sustained increase in serum urate over a period of six months, it does not alter the markers of bone turnover in postmenopausal women. The hypothesis that urate has direct biological effects on bone turnover is not confirmed by these findings.